JOURNAL BROWSE
Search
Advanced SearchSearch Tips
The C609T (Pro187Ser) Null Polymorphism of the NQO1 Gene Contributes Significantly to Breast Cancer Susceptibility in North Indian Populations: a Case Control Study
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
The C609T (Pro187Ser) Null Polymorphism of the NQO1 Gene Contributes Significantly to Breast Cancer Susceptibility in North Indian Populations: a Case Control Study
Yadav, Prasant; Mir, Rashid; Nandi, Kajal; Javid, Jamsheed; Masroor, Mirza; Ahmad, Imtiyaz; Zuberi, Mariyam; Kaza, RCM; Jain, SK; Khurana, Nita; Ray, Prakash Chandra; Saxena, Alpana;
  PDF(new window)
 Abstract
Background: Worldwide, breast cancer is the most common cancer among women and is a leading cause of cancer death. In the present study, we investigated the NQO1 C609T genotypic and allelic distribution in north Indian breast cancer patients. Materials and Methods: The genotypic distribution of the NQ01 C609T polymorphism was assessed in 100 invasive ductal carcinoma (IDC) breast cancer patients and 100 healthy controls using allele specific PCR (AS-PCR). Results: A lower frequency of the CC genotype was found in breast cancer patients (24%) than in the controls. On the other hand, TT genotype frequency was also found to be higher in female healthy controls (32%) than the female breast cancer patients (20%). The frequencies of all three genotypes CC, CT, TT in patients were 24%, 56% and 20% and in healthy controls 50%, 22% and 32% respectively. We did not find any significant correlation between the NQO1 C609T polymorphism and age group, grading, menopausal status and distant metastasis. A less significant association was found between the NQ01 C609T polymorphism and the stage of breast cancer (X2
 Keywords
Breast cancer;NAD(P)H:quinoneoxidoreductase 1 polymorphism;invasive ductal carcinoma;India;
 Language
English
 Cited by
 References
1.
Ambrosone CB (2000). Oxidants and antioxidants in breast cancer. Antioxid Redox Signal, 2, 903-17. crossref(new window)

2.
di Martino E1, Hardie LJ, Wild CP, et al (2007). "The NAD(P) H:quinone oxidoreductase I C609T polymorphism modifies the risk of barrett esophagus and esophageal adenocarcinoma." Genetics Med, 9, 341-7. crossref(new window)

3.
Fagerholm R, Hofstetter B, Tommiska J, et al (2008). NAD(P) H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet, 40, 844-53. crossref(new window)

4.
Hamajima N, Matsuo K, et al (2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.

5.
Jana Sarmanova, Simona Su sova, Ivan Gut, et al (2004). Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Human Genetics, 12, 848-54. crossref(new window)

6.
Jay H. Fowke, Xiao-Ou Shu, Qi Dai, et al (2004). Genetic Polymorphisms Modification by NAD(P)H:Quinone oxoreductase (NQO1) oral contraceptive use and breast cancer risk. cancer epidemiol biomarkers prev, 13, 1308-15.

7.
Kuehl BL, Paterson JW, Peacock JW, et al (1995). Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer, 72, 555-561. crossref(new window)

8.
Lewis SJ, NM Cherry (2001). Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177-183. crossref(new window)

9.
Menzel HJ, J Sarmanova, et al (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independentpopulations. Br J Cancer, 90, 1989-94. crossref(new window)

10.
Moran JL, Siegel D, Ross D (1999). A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA, 96, 8150-5. crossref(new window)

11.
Menzel HJ, J Sarmanova (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer, 90, 1989-94. crossref(new window)

12.
Nowell SA, Ahn J, Ambrosone CB, et al (2004). Gene-nutrient interactions in cancer etiology. Nutr Rev, 62, 427-38. crossref(new window)

13.
Niwa Y, K Hirose (2005). Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecologic Oncol 96, 423-9. crossref(new window)

14.
Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG (2002) NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a huge review. Genet Med, 4, 62-70 crossref(new window)

15.
Rauth AM, Goldberg Z, Misra V (1997) DT-diaphorase: possible roles in cancer. chemotherapy and carcinogenesis. Oncol Res, 9, 339-49.

16.
Ross D, Traver RD, Siegel D, et al (1996). A polymorphism in NAD(P)H: quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer, 74, 995-6. crossref(new window)

17.
Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9, 113-21. crossref(new window)

18.
Siegel D, Anwar A,Winski SL, Kepa JK, Dowd KL (2001). Rapid polyubiquination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol, 59, 263-8.

19.
Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP (2011) Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers, 15, 343-349. crossref(new window)

20.
Traver RD, Siegel D, Beall HD, et al (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75. crossref(new window)

21.
Wyllie S, Liehr JG (1997) Release of iron from ferritin storage by redox cyclingof stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen. Arch Biochem Biophys, 346, 180-6. crossref(new window)